96 results about "Cancer suppressor gene" patented technology

The present invention addresses the problem of providing malignant stem cells that can be grown in vitro and are useful in cancer therapy research and drug discovery research for cancer therapy, a method for producing same, cancer cells induced from the cells, and use for the cells. Provided are induced malignant stem cells that can be grown in vitro, the induced malignant stem cells being characterized in (1) having at least one type of abnormality selected from among (a) abnormal methylation (hypermethylation or hypomethylation) of a cancer suppressor gene or cancer-related gene region in the endogenous genome DNA, (b) somatic mutation of a cancer suppressor gene in the endogenous genome DNA or somatic mutation of an endogenous cancer-related gene, (c) abnormal expression (increased expression or decreased / lost expression); of an endogenous cancer gene or endogenous cancer suppressor gene, (d) abnormal expression (increased expression or decreased / lost expression) of non-coding RNA such as endogenous cancer-related micro RNA, (e) abnormal expression (increased expression or decreased / lost expression) of an endogenous cancer-related protein, (f) endogenous cancer-related metabolism abnormality (hypermetabolism or hypometabolism), or (g) abnormal endogenous cancer-related carbohydrate; and (2) expressing the POU5F1 gene, NANOG gene, SOX2 gene, and ZFP42 gene.

The invention relates to a fluorescence quantitative PCR (Polymerase Chain Reaction) diagnostic kit for rapid detection of mRNA expression level of a BRCA1 gene. The kit comprises BRCA1gene primer, a reference gene GAPDH primer and a Taqman fluorescence probe. The BRCA1 is an important cancer suppressor gene, and proteins coded by the BRCA1 gene play an important role in DNA damage and repair. A fluorescence quantitative PCR with high sensitivity and specificity is employed to detect the mRNA expression level of BRCA1; and a detection result has substantially increased specificity and sensitivity. The kit provides a novel rapid simple gene diagnostic technique for whether a clinical malignant tumor patient should use platinum chemotherapeutics and antimicrotubular medicaments.

The invention discloses a drug carrier for general administration through intravenous injection, a preparation method and technology thereof applied to tumor gene therapy, belonging to the field of tumor targeted therapy. The carrier provided by the invention is a novel liposome formed by DOTAP or other analogues and lecithin or derivatives thereof according to a mole ratio of 20: (7-13), can form a stable composite with bioactive substances, and can directionally and efficiently carry the bioactive substances out of the human body to culture and carry into target cells in the human body. Thecomposite provided by the invention has larger carrying capacity; the particle size is greatly decreased, namely, the particle size is optimized to 200nm and below; high transfection efficiency is kept under the condition of high serum concentration; when the carrier package provided by the invention carries cancer suppressor gene or cell suicide gene DNA and the like, the formed composite can betargeted and carried out of the human body to culture, carried away from the human body and carried into the tumor cells in the human body so as to achieve the purpose of carrying out gene therapy onthe tumor.

The invention relates to a method for establishing a pancreatic cancer model, and belongs to the technical field of the establishment of an animal model. According to the method, a slow virus for over-expressing one cancer gene and simultaneous knocking down two cancer suppressor genes is constructed according to cancer genes and cancer suppressor genes having the maximum mutation rate in human pancreatic cancer in TCGA database, and the slow virus is applied to the pancreas head of a tree shrew through orthotopic injection so as to induce pancreatic cancer of the tree shrew; and specifically, the method comprises the following steps: (1) construction of a slow virus vector; (2) virus packaging, titre determination and in vitro verification; (3) virus injection; and (4) monitoring and pathological investigation of the tree shrew. The method disclosed by the invention has the advantages that the method is short in inducing cycle, high and stable in morbidity, and simple and convenient in operation, and is capable of rapidly and effectively establishing a tree shrew pancreatic cancer model for simulating the genetic mechanism of human pancreatic cancer to the greatest extent; and the pancreatic cancer model is applicable to the research of the pathogenesis of human pancreatic cancer, the exploration of cancer therapy targets and the development of novel antineoplastic drugs, so as to offer a reference for the treatment of human pancreatic cancer.

The invention discloses a genetic therapy breast cancer drug preparation method based on microfluidic chip, which includes that: the method adopts biological molecules as computation medium to compute the cancer-related gene expression through biochemical reaction; when the result meets the requirement, the anti-cancer drug is automatically synthesized and released in targeted manner; the anti-cancer drug is complete suicide gene; the biological molecules used as computation medium are DNA molecules and / or enzyme; the oncogene related to breast cancer includes: C-erbB-2, EGFR, c-myc, ras, int-2, bcl-2, BAG-1, BCSG-2 and survivin; the cancer suppressor gene related to breast cancer includes P53, nm23, PTEN, Rb, P16, P21, CHEK2, BRCA1 and BRCA2. The invention can synthesize and release anti-cancer drugs for breast cancer on specified conditions; and the anti-cancer drugs are complete suicide gene. The method can be combined with the nanometer technology and micromachining technology to help improve the treatment effect.

The invention discloses a cancer suppressor gene ATOH8 and application of an encoding protein thereof. A novel cancer suppressor gene ATOH8 is found. As proved by in-vivo and in-vitro functional study analysis, the cancer suppressor gene plays an important role in the incidence and development processes of cancers. By using the ATOH8, stem cell differentiation can be facilitated, and the drug tolerance of cancer stem cells to chemotherapeutic medicaments can be lowered. Moreover, a novel effective way is provided for induction of the formation of iPSCs (induced Pluripotent Stem Cells) by means of expression of silent ATOH8. By using the cancer suppressor gene ATOH8, novel diagnosis and treatment methods and a medicament screening platform are provided for neoplastic diseases.

The invention belongs to the field of gene treatment, provides a new gene therapy product, and specifically relates to a cationic liposome compound of cancer suppressor gene LKB1 eukaryotic expression plasmid as well as a preparation method and an anti-tumor effect thereof. The gene expression carrier contains genes encoding human LKB1 protein and can express the human LKB1 protein in eukaryotic cells. Based on experiments, the cationic liposome compound of cancer suppressor gene LKB1 eukaryotic expression plasmid, disclosed by the invention, has excellent functions of resisting tumor growth and invasion and metastasis so as to provide a new selection for the tumor treatment.